A
Annexon, Inc. (ANNX)
NMS – Real vaqt narxi. Valyuta: USD
5.36
+0.02 (0.37%)
Bozor ochiq: Aug 12, 2026, 11:51 AM EDT
5.38
+0.04 (0.75%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
5.36
+0.02 (0.37%)
Bozor ochiq: Aug 12, 2026, 11:51 AM EDT
5.38
+0.04 (0.75%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Annexon, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, yalligʻlanish bilan bogʻliq kasalliklarni davolash uchun dori-darmonlarni kashf qiladi va ishlab chiqadi. Kompaniya Tanruprubartni taqdim etadi, bu tadqiqotdagi toʻliq uzunlikdagi monoklonal antitelodir, u Guillain-Barre sindromi bilan ogʻrigan bemorlarni davolash uchun III bosqich klinik sinovida; Xantington kasalligini davolash uchun II bosqich klinik sinovini yakunlagan; va amyotrofik lateral sklerozni davolash uchun IIa bosqich klinik sinovidagi. U shuningdek, geografik atrofiya bilan ogʻrigan bemorlarni davolash uchun III bosqich dasturida boʻlgan antigen-bogʻlovchi fragment (Fab) boʻlgan ANX007ni ishlab chiqmoqda; va avtoimmun koʻrsatmalar uchun I bosqich klinik sinovlarida boʻlgan yangi ogʻiz orqali qabul qilinadigan kichik molekulyar inhibitor ANX1502ni ishlab chiqmoqda. Bundan tashqari, u lupus nefriti bilan ogʻrigan bemorlarni davolash uchun I bosqich klinik sinovida boʻlgan C1q bloklovchi Fab boʻlgan ANX009ni ishlab chiqadi. Kompaniya 2011 yilda roʻyxatga olingan va shtab-kvartirasi Kaliforniyaning Brisbane shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer |
| Dr. Sunil Mehta Pharm.D. | Senior VP of Medical Affairs |
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board |
| Mr. Douglas E. Love Esq., J.D. | CEO, President & Director |
| Mr. Henk-Andre Kroon M.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-10 | 8-K | d130710d8k.htm |
| 2026-08-06 | 8-K | d159969d8k.htm |
| 2026-07-30 | 8-K | d113783d8k.htm |
| 2026-06-12 | 8-K | d123141d8k.htm |
| 2026-05-07 | 8-K | annx-20260507.htm |
| 2026-05-07 | 10-Q | annx-20260331.htm |
| 2026-04-27 | DEFA14A | ny20063060x3_defa14a.htm |
| 2026-04-27 | DEF 14A | ny20063060x2_def14a.htm |
| 2026-04-27 | ARS | ny20063060x4_ars.pdf |
| 2026-04-16 | PRE 14A | ny20063060x1_pre14a.htm |
| Senior Vice President of Translational Medicine |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer |
| Mr. Shikhar Agarwal M.B.A. | Senior VP & Head of Commercial |
| Ms. Jennifer Lew CPA | Executive VP, CFO & Corporate Secretary |
| Ms. Linda A. Fitzpatrick | Chief Human Resources Officer |